Sebela Pharmaceuticals
Developing therapies for gastrointestinal diseases and women's health
Based in GA
AI Overview
With $400K in lobbying spend across 11 quarterly filings, Sebela Pharmaceuticals is an active lobbying client. Their lobbying covers 1 issue area. Active from 2023 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2023 | $40K |
| 2024 | $160K |
| 2025 | $200K |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Sebela Pharmaceuticals disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues
general healthcare issues; coverage for prescription bowel prep products
Affordable Care Acts Preventative Services Coverage mandate requires ACA compliant health plans to cover colonoscopy screenings without cost sharing . In 2016, CMS released guidance clarifying that bo
The Affordable Care Acts Preventive Services Coverage mandate requires ACA-compliant health plans to cover colonoscopy screenings without cost sharing. In 2016, CMS issued guidance clarifying that bow
Discussed the need for Congressional oversight of CMS to ensure enforcement of the preventive services mandate, specifically requiring coverage of bowel preparation medications without cost-sharing wh
Requesting CMS change guidance on Bowel Prep Coverage for Screening Colonoscopies
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.